The Pfizer-BioNTech COVID-19 vaccine can be administered as a single booster dose to individuals 5 to 11 years of age at least 5 months after completion of the primary series.
The KidCOVE study included children 6 months to less than 6 years of age who received either two 25mcg doses of mRNA-1273 or placebo, separated by 28 days.
As the medical field shifted its priorities to treating COVID-19 at the start of the pandemic, routine immunization was one of the many medical fields to experience disruption. What was the scope of this disruption and what are possible ways to address it?
Two observational studies and a modelling study suggest that meningitis vaccine could offer some protection against gonorrhea.
Researchers examine the effectiveness of text message reminder systems on HPV vaccination rates among teens.
Vaccination within teratogenic window not linked to presence of congenital anomalies identified on ultrasonography.
CDC updates hepatitis B vaccination recommendation for adults
The Emergency Use Authorization was based on safety and immunogenicity data provided to the Agency.
The KidCOVE study is currently evaluating the immunogenicity, safety, and tolerability of the mRNA-1273 vaccine in healthy children.
Immunologists Prakash Nagarkatti and Mitzi Nagarkatti of the University of South Carolina explain what makes it different from previous variants, whether there will be another surge in the US and how best to protect yourself.
This submission comes shortly after Pfizer and BioNTech submitted an EUA request for an additional booster dose of their COVID-19 vaccine for adults 65 years of age and older.
COVID-19 research is expected to yield medical and scientific dividends for the treatment of influenza, cancer, cystic fibrosis, and other chronic diseases.
Although the facts in this month’s Legal Advisor predate the COVID-19 pandemic, the legal impact is likely to be relevant in cases that involve religious exemption for mandatory vaccines.
In this Q&A, Erica Johnson, MD, discussed the transition from pandemic to endemic in regard to COVID-19 infection.
Suzette Oyeku, MD, MPH, speaks to us about the existing disparities in childhood COVID-19 vaccine access and the role of providers in ensuring vaccine uptake among pediatric populations.
The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes.
The rise in vaccination rates among teens is most likely due to the surge of the Omicron variant of COVID-19, which started in late November 2021.
Vaccine effectiveness 75% during 2019 to 2020 season, when vaccine-mismatched viruses predominated.
Findings from an ongoing randomized, placebo-controlled, observer-blind phase 3 trial showed Spikevax was 93.2% effective at preventing COVID-19.
ACIP recommends PCV20 alone or PCV15 in series with PPSV23 for all aged 65 years and older or younger adults at risk.